BioNTech (BNTX) lists Chief People Officer Kylie Jimenez as insider in Form 3

Rhea-AI Filing Summary

BioNTech SE filed an initial insider ownership report for Chief People Officer Kylie Jimenez. This Form 3 establishes her status as a reporting person under U.S. securities rules. The filing does not list any transactions or option exercises; it simply opens ongoing disclosure of future activity.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jimenez Kylie

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Humza Bokhari, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioNTech (BNTX) Form 3 filing for Kylie Jimenez mean?

The Form 3 filing for Kylie Jimenez records her as an insider of BioNTech SE. It is an initial ownership statement, triggering ongoing disclosure duties for future trades or grants in BioNTech securities under U.S. securities regulations.

Does the BioNTech (BNTX) Form 3 for Kylie Jimenez show any stock transactions?

No, the Form 3 for Kylie Jimenez does not report any stock purchases, sales, or option exercises. It only identifies her as Chief People Officer and a reporting insider, without detailing specific holdings or recent trading activity in BioNTech shares.

Who is identified as a reporting insider of BioNTech (BNTX) in this Form 3?

The filing identifies Kylie Jimenez as a reporting insider of BioNTech SE. She is listed as an officer with the title Chief People Officer, which subjects her to ongoing reporting obligations for future transactions in BioNTech securities.

Is the BioNTech (BNTX) Form 3 for Kylie Jimenez a buy or sell signal?

The Form 3 is not a buy or sell signal; it is purely administrative. It registers Kylie Jimenez as an insider and does not include any share purchases, sales, or other transactions that might indicate market sentiment or trading intent.

Why is BioNTech (BNTX) required to file a Form 3 for Kylie Jimenez?

Form 3 is required when someone becomes an insider, such as a key officer, of a public company. For BioNTech SE, listing Kylie Jimenez as Chief People Officer ensures regulatory transparency for any future changes in her beneficial ownership of company securities.